Mateon Therapeutics

October 9, 2017October 9, 2017

After Disappointing Results, Mateon to End FOCUS Trial for CA4P in Ovarian Cancer Patients

News

Mateon Therapeutics announced that it is immediately ending the FOCUS trial of CA4P to treat platinum-resistant ovarian cancer, based on disappointing interim results. The results showed that CA4P (fosbretabulin) did not significantly ... Read more

September 20, 2017

CA4P Is Well Tolerated, May Benefit Platinum-resistant Ovarian Cancer Patients, Trial Shows

News

Data from the second interim analysis of the ongoing Phase 2/3 FOCUS study has shown that Mateon Therapeutics’ CA4P (combretastatin a4-phosphate), also known as fosbretabulin, may prolong the time to disease ... Read more

June 14, 2017June 14, 2017

Update on FOCUS Trial of CA4P in Ovarian Cancer Expected in Late Summer

News

Second preliminary results from the FOCUS Phase 2/3 trial assessing the safety and effectiveness of Mateon Therapeutics’ drug candidate CA4P in combination with standard-of-care therapies for platinum-resistant ovarian cancer are expected ... Read more

April 21, 2017April 21, 2017

CA4P Combo Treatment Shows Promise in Platinum-Resistant Ovarian Cancer Trial

News

An interim analysis from the Phase 2/3 clinical trial assessing Mateon Therapeutics‘ CA4P suggests the drug therapy is safe and effective in platinum-resistant ovarian cancer patients, when used in combination ... Read more